-- Receives Recognition in Two Leading Industry Publications --
BRITISH COLUMBIA, Canada, Sept. 29 /CNW/ -- InNexus Biotechnology Inc.,
(OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug
development company commercializing the next generation of monoclonal
antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces
Jeff Morhet, CEO and Chairman, to present during BioContactQuebec 2008. The
company also announces the featuring of Mr. Morhet in two leading
publications, Genetic Engineering & Biotechnology News and The PharmaVoice
List of Top 100 in Life Sciences.
During BioContactQuebec 2008, InNexus' CEO will present on Thursday,
October 2nd at 2:30-3:00 PM EDT on the Salle Laval at the Chateau Frontenac,
Quebec. The presentation will include a company overview and information
about InNexus' unique business strategy, its DXL(TM) technology platform and
upcoming company milestones. Investors, venture capitalists, company
executives, scientists and other industry leaders will attend the symposium.
Also announced, the most recent edition of Genetic Engineering &
Biotechnology News features InNexus CEO Morhet in the article, Peptide Drugs
Becoming More Prevalent, where he discusses the pharmaceutical industry and
outlines InNexus' DXL(TM) antibody enhancement technology platform.
The company also announced Mr. Morhet has also been named to
PharmaVOICE's list of the "100 Most Inspiring People in the Life Sciences",
July/August Edition. The publication illustrates those individuals who think
outside the box, pioneering new paths to success and inspire their colleagues
in the industry. http://www.pharmavoice.com
About BioContactQuebec 2008
BioContactQuebec 2008 is a biopharmaceutical partnership symposium
gathering over 1200 participants and more than 150 biopharmaceutical
companies, coming from Canada, the United States, Asia and Europe, presenting
in different sectors of activities (diagnostics, therapeutics and services)
and disciplines such as cancer, immunology and inflammation.
InNexus is a drug development company commercializing the next generation
of monoclonal antibodies based on its DXL(TM) technology, which improves the
potency of existing antibody products while opening new markets and disease
applications. DXL(TM) antibodies utilize unique, novel and patented methods
and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management
based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-
house developmental facilities. These development resources provide validation
of protein and peptide discoveries, enabling InNexus (and its strategic
partners) to advance novel drug therapeutics and diagnostics. To learn more
about InNexus, please visit http://www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release. This news
release may contain assumptions, estimates, and other forward-looking
statements that involve inherent risks and uncertainties and are subject to
factors, many of which are beyond the Company's control that may cause actual
results or performance to differ materially from those currently anticipated
in such statements.
For further information:
For further information: Wade Brooksby, Chief Financial Officer of
InNexus Biotechnology Inc., +1-480-862-7500 Web Site: http://www.ixsbio.com